Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$23.17
+2.0%
$30.44
$22.27
$59.61
$1.10B1.38732,524 shs947,750 shs
Axonics, Inc. stock logo
AXNX
Axonics
$66.47
-0.6%
$68.00
$47.59
$69.68
$3.41B0.561.00 million shs1.07 million shs
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Glaukos Co. stock logo
GKOS
Glaukos
$101.06
+2.1%
$91.93
$45.38
$102.33
$5.07B1.08491,609 shs351,098 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+2.03%+0.30%-18.62%-31.00%-44.02%
Axonics, Inc. stock logo
AXNX
Axonics
-0.55%-1.29%-2.62%-2.34%+10.65%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%+0.10%
Glaukos Co. stock logo
GKOS
Glaukos
+2.14%+4.25%+14.74%+9.82%+109.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
1.7077 of 5 stars
3.51.00.00.01.82.50.6
Axonics, Inc. stock logo
AXNX
Axonics
3.1834 of 5 stars
1.22.00.04.12.72.51.9
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.2344 of 5 stars
0.00.00.04.20.01.70.6
Glaukos Co. stock logo
GKOS
Glaukos
3.4456 of 5 stars
2.42.00.04.42.52.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$52.63127.13% Upside
Axonics, Inc. stock logo
AXNX
Axonics
2.38
Hold$70.736.40% Upside
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
2.78
Moderate Buy$99.80-1.25% Downside

Current Analyst Ratings

Latest ATRC, AXNX, CMD, GKOS, and CSII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
4/8/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
4/3/2024
Glaukos Co. stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
3/25/2024
Glaukos Co. stock logo
GKOS
Glaukos
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $120.00
3/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
2/29/2024
Axonics, Inc. stock logo
AXNX
Axonics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$71.00
2/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$83.00 ➝ $103.00
2/22/2024
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$105.00 ➝ $108.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $58.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.81N/AN/A$9.84 per share2.35
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.25$0.13 per share529.18$12.59 per share5.28
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Glaukos Co. stock logo
GKOS
Glaukos
$314.71M16.12N/AN/A$9.46 per share10.68

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.66N/AN/AN/A-7.62%-7.55%-5.83%5/1/2024 (Confirmed)
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.13N/A103.86N/A-1.66%-1.00%-0.90%5/6/2024 (Estimated)
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.78N/AN/AN/A-42.79%-22.67%-11.50%5/1/2024 (Confirmed)

Latest ATRC, AXNX, CMD, GKOS, and CSII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.20N/A+$0.20N/AN/AN/A  
5/1/2024N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$0.59N/A+$0.59N/AN/AN/A  
2/28/2024Q4 2023
Axonics, Inc. stock logo
AXNX
Axonics
$0.06$0.13+$0.07$0.13$107.33 million$109.70 million
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
Axonics, Inc. stock logo
AXNX
Axonics
N/A
10.73
8.98
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Glaukos Co. stock logo
GKOS
Glaukos
0.77
5.34
4.78

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Glaukos Co. stock logo
GKOS
Glaukos
99.04%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Glaukos Co. stock logo
GKOS
Glaukos
7.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20048.38 million46.83 millionOptionable
Axonics, Inc. stock logo
AXNX
Axonics
79751.00 million50.06 millionOptionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90750.19 million46.98 millionOptionable

AXNX, ATRC, CMD, CSII, and GKOS Headlines

SourceHeadline
Glaukos (GKOS) Set to Announce Quarterly Earnings on WednesdayGlaukos (GKOS) Set to Announce Quarterly Earnings on Wednesday
americanbankingnews.com - April 24 at 4:58 AM
Glaukos’ Tiny Medical Devices Fuel Expansion for OphthalmologyGlaukos’ Tiny Medical Devices Fuel Expansion for Ophthalmology
ocbj.com - April 23 at 12:57 AM
Glaukos (NYSE:GKOS) vs. Revolutions Medical (OTCMKTS:RMCP) Head to Head SurveyGlaukos (NYSE:GKOS) vs. Revolutions Medical (OTCMKTS:RMCP) Head to Head Survey
americanbankingnews.com - April 22 at 1:42 AM
Glaukos (NYSE:GKOS) Trading 3.4% Higher Glaukos (NYSE:GKOS) Trading 3.4% Higher
americanbankingnews.com - April 21 at 4:56 AM
Glaukos (NYSE:GKOS) Trading Up 3.4%Glaukos (NYSE:GKOS) Trading Up 3.4%
marketbeat.com - April 19 at 1:58 PM
Louisiana State Employees Retirement System Invests $1.94 Million in Glaukos Co. (NYSE:GKOS)Louisiana State Employees Retirement System Invests $1.94 Million in Glaukos Co. (NYSE:GKOS)
marketbeat.com - April 19 at 5:28 AM
Glaukos Co. (NYSE:GKOS) Given Consensus Rating of "Moderate Buy" by BrokeragesGlaukos Co. (NYSE:GKOS) Given Consensus Rating of "Moderate Buy" by Brokerages
americanbankingnews.com - April 19 at 2:18 AM
Glaukos Announces the Release of its 2023 Sustainability ReportGlaukos Announces the Release of its 2023 Sustainability Report
businesswire.com - April 16 at 4:05 PM
Glaukos Co. (NYSE:GKOS) Shares Sold by SG Americas Securities LLCGlaukos Co. (NYSE:GKOS) Shares Sold by SG Americas Securities LLC
marketbeat.com - April 16 at 4:07 AM
Heres Why You Should Retain Glaukos (GKOS) Stock for NowHere's Why You Should Retain Glaukos (GKOS) Stock for Now
zacks.com - April 15 at 9:21 AM
Speaker Johnson welcomes Japanese PM Kishida and his wife to the CapitolSpeaker Johnson welcomes Japanese PM Kishida and his wife to the Capitol
ca.news.yahoo.com - April 13 at 1:01 AM
Glaukos (GKOS) Gains Nearly 25% YTD: Whats Driving the Rally?Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
zacks.com - April 12 at 10:26 AM
Is Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)?Is Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)?
finance.yahoo.com - April 11 at 12:03 PM
Glaukos (NYSE:GKOS) PT Raised to $100.00 at MizuhoGlaukos (NYSE:GKOS) PT Raised to $100.00 at Mizuho
marketbeat.com - April 11 at 8:25 AM
Glaukos Co. (NYSE:GKOS) COO Sells $6,008,206.47 in StockGlaukos Co. (NYSE:GKOS) COO Sells $6,008,206.47 in Stock
insidertrades.com - April 11 at 6:16 AM
Glaukos CFO sells over $163k in company stockGlaukos CFO sells over $163k in company stock
investing.com - April 11 at 2:02 AM
Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 59,801 SharesGlaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 59,801 Shares
marketbeat.com - April 10 at 9:16 PM
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
finance.yahoo.com - April 10 at 10:29 AM
Peregrine Capital Management LLC Has $7.88 Million Position in Glaukos Co. (NYSE:GKOS)Peregrine Capital Management LLC Has $7.88 Million Position in Glaukos Co. (NYSE:GKOS)
marketbeat.com - April 10 at 9:49 AM
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
businesswire.com - April 10 at 7:00 AM
Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,372 SharesGlaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,372 Shares
insidertrades.com - April 10 at 5:14 AM
Glaukos Co. (NYSE:GKOS) CFO Sells $137,940.88 in StockGlaukos Co. (NYSE:GKOS) CFO Sells $137,940.88 in Stock
marketbeat.com - April 9 at 9:14 PM
Glaukos (GKOS) Hits 52-Week High: Whats Driving the Stock?Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
zacks.com - April 8 at 11:46 AM
Glaukos Co. (NYSE:GKOS) COO Sells $19,314.00 in StockGlaukos Co. (NYSE:GKOS) COO Sells $19,314.00 in Stock
insidertrades.com - April 6 at 7:57 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Axonics logo

Axonics

NASDAQ:AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Cantel Medical logo

Cantel Medical

NYSE:CMD
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.
Cardiovascular Systems logo

Cardiovascular Systems

NASDAQ:CSII
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.
Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.